CT Atlantic Overview

  • Founded
  • 2008
  • Status
  • Out of Business
  • Employees
  • 3
  • Latest Deal Type
  • Out of Business

CT Atlantic General Information


Provider of drugs designed to provide treatment of cancer. The company's drugs are use to treat cancer using antibodies derived from cohorts of patients, enabling patients to begin treatment more quickly and result in a higher likelihood of a successful treatment.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • Wagistr. 14
  • 8952 Schlieren
  • Switzerland
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

CT Atlantic Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Out of Business 01-Oct-2018 00.00 Completed Out of Business
1. Early Stage VC (Series A) 12-Jan-2009 00.00 00.00 Completed Startup
To view CT Atlantic’s complete valuation and funding history, request access »

CT Atlantic Executive Team (4)

Name Title Board Seat Contact Info
Edward Stuart Ph.D Co-Founder & Chief Executive Officer
Alexander Knuth Scientific Founder
You’re viewing 2 of 4 executive team members. Get the full list »

CT Atlantic Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial